Retatrutide — offered as research material under the identifier GLP-3RT — is a synthetic 39-amino-acid peptide studied in vitro as a triple agonist of three class B G protein-coupled receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). By engaging all three targets with one molecule, it extends the incretin-receptor pharmacology of dual agonists to include glucagon-receptor signaling. This overview covers its receptor targets, cell-based mechanism, and molecular structure. The material described here is for laboratory research use only; not for human or veterinary use.
Retatrutide is frequently studied alongside dual agonists to isolate the contribution of GCGR activation to downstream cyclic AMP (cAMP) signaling. The discussion below is limited to molecular pharmacology characterized in recombinant cell lines and preclinical systems.
Receptor Targets: GLP-1R, GIPR, and GCGR
All three of these targets belong to the class B (secretin-family) GPCRs and couple to the stimulatory G protein (Gs). GLP-1R and GIPR are the two canonical incretin receptors; the glucagon receptor is their close structural relative and responds to the peptide hormone glucagon. Because the three receptors share architecture and a common Gs/cAMP output, a single peptide can be engineered to bind all three, which is the defining property of a triple agonist.
In recombinant cell assays, retatrutide is characterized as a potent agonist at GLP-1R and GCGR with somewhat lower relative potency at GIPR — an in-vitro potency profile that distinguishes it from dual agonists such as tirzepatide. Researchers quantify these differences with binding assays and cAMP accumulation assays run in parallel across cells expressing each human receptor.
Mechanism of Action Studied In Vitro
At each receptor, agonist binding stabilizes the active class B GPCR conformation, catalyzes GDP-to-GTP exchange on the Gs alpha subunit, and stimulates adenylyl cyclase to raise intracellular cAMP. Elevated cAMP then activates protein kinase A (PKA) and Epac, the standard downstream readouts in these experiments.
The research interest in retatrutide lies in the convergence and divergence of three signaling inputs. GLP-1R and GIPR activation is studied primarily in pancreatic- and neuronal-lineage cell models, whereas glucagon-receptor signaling is most often examined in hepatocyte-derived cells, where GCGR classically drives cAMP/PKA cascades and, in some contexts, Gq-linked calcium signaling. Adding GCGR engagement to incretin-receptor activity lets researchers dissect how a single molecule integrates these pathways in vitro. All such observations derive from cell-based and preclinical models, not human studies.
Because retatrutide activates three receptors with distinct tissue-expression patterns, it is also used to study functional selectivity — how relative potency and efficacy at each receptor shape the net cAMP signal measured in a given cell background.
Molecular Structure and Modifications
Retatrutide is a linear 39-residue peptide with a molecular weight of approximately 4.7 kDa, built on a GIP-based backbone and modified to broaden its receptor coverage to include GCGR. Like other long-acting incretin-class research peptides, it combines protease-resistant substitutions with a lipidation strategy for stability.
Non-proteinogenic aminoisobutyric acid (Aib) residues are incorporated to block N-terminal cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates native incretins. A fatty-acid (lipid) moiety is conjugated through a linker to a lysine side chain, promoting reversible serum-albumin binding that supports extended exposure in preclinical pharmacokinetic studies. Precise amino-acid substitutions at the receptor-interface positions are what tune the molecule toward balanced GLP-1R and GCGR activity.
The result is a single sequence whose backbone, protease resistance, and albumin-binding lipid together support triple-receptor activity and the extended exposure needed for preclinical research protocols.
Research-Use Handling
GLP-3RT research material is generally supplied as a sterile-filtered, lyophilized white powder. In the laboratory it is reconstituted in bacteriostatic or sterile water to prepare stock solutions for binding and signaling assays, with working concentrations determined by the assay design chosen by the investigator. Lyophilized powder is stored desiccated and frozen; reconstituted stock is refrigerated and used within a limited window to limit degradation and oxidation.
Because triple-agonist signaling assays are sensitive to peptide impurities, purity and identity should be confirmed before use. Each research lot is analyzed by HPLC for purity and mass spectrometry for identity, with results reported on a Certificate of Analysis. This peptide is intended solely for in-vitro and preclinical research and is not for human or veterinary use.
Frequently Asked Questions
What does triple agonist mean for retatrutide? It means one peptide activates three receptors — GLP-1R, GIPR, and GCGR — each a Gs-coupled class B GPCR that signals through cAMP. The added glucagon-receptor activity is what separates it from dual agonists.
How does GLP-3RT differ from tirzepatide? Tirzepatide is a dual GLP-1R/GIPR agonist, whereas retatrutide adds glucagon-receptor (GCGR) activation for three targets in total. In cell models, this lets researchers compare two- versus three-receptor signaling directly.
Why include the glucagon receptor? GCGR is a close structural relative of the incretin receptors and shares the Gs/cAMP output, so adding it lets investigators study integrated multi-receptor pharmacology in vitro. In the research literature, glucagon-receptor signaling is examined mainly in hepatocyte-derived cell models.
Is retatrutide (GLP-3RT) approved for human use? No. It is supplied strictly as a research chemical for laboratory research use only; not for human or veterinary use, and is intended for qualified researchers conducting in-vitro or preclinical work.
To go deeper on the individual targets, see the glossary entries for the glucagon receptor, GLP-1 receptor, and GIP receptor, or browse the complete research catalog. Every Ascension Labs peptide is supplied for laboratory research use only; not for human or veterinary use.